Get started
Author

Anna V. Senina

Observed names: A Senina, A. Senina, Anna Senina, Anna V Senina
OpenAlex ID: A5062000628
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
2019 · Christopher A. Eide, Matthew S. Zabriskie, et al. · Cancer Cell · 248
PDF
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
2014 · A M Eiring, B D G Page, et al. · Leukemia · 132
A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas
2014 · Jason M. Foulks, Kent J. Carpenter, et al. · Neoplasia · 98
Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2013 · K. Mark Parnell, Jason M. Foulks, et al. · Molecular Cancer Therapeutics · 72
SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
2021 · Dongqing Yan, Anca Franzini, et al. · Blood Cancer Discovery · 66
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
2018 · William L. Heaton, Anna V. Senina, et al. · Leukemia · 53
PDF
Oncolysis by paramyxoviruses: preclinical and clinical studies
2015 · Olga V Matveeva, Zong S Guo, et al. · Molecular Therapy — Oncolytics · 40
PDF
Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
2018 · Dongqing Yan, Anthony D. Pomicter, et al. · Clinical Cancer Research · 39
Erratum: Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
2017 · A M Eiring, B D G Page, et al. · Leukemia · 23
PDF
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis
2021 · Helong Zhao, Anthony D. Pomicter, et al. · Blood · 20
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism
2022 · Mayra A. Gonzalez, Idaly M. Olivas, et al. · Clinical and Translational Medicine · 16
PDF
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm
2015 · Anthony D. Pomicter, Anna M. Eiring, et al. · Experimental Hematology · 9
PDF
Selective in vitro and in vivo anti-tumor activity of PRLX 93936 in biological models of melanoma and ovarian cancer
2008 · S. R. Sahasrabudhe, S. Lai, et al. · Journal of Clinical Oncology · 8
Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells
2020 · Hein Than, Anthony D. Pomicter, et al. · Leukemia · 7
Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis
2016 · Dongqing Yan, Srinivas K. Tantravahi, et al. · Blood · 4
SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia
2018 · Dongqing Yan, Anthony D. Pomicter, et al. · Blood · 3
Global DNA Hypermethylation in Chronic Lymphocytic Leukemia Correlates with Progressive Disease.
2005 · Margaret K. Yu, Aniko Szabo, et al. · Blood · 3
Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants
2019 · Christopher A. Eide, Matthew S. Zabriskie, et al. · Blood · 2
Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia
2017 · Hein Than, Anthony D. Pomicter, et al. · Blood · 1
TNFR2 Signaling Promotes Myeloproliferative Disease Progression: A Role for MAPK8?
2016 · William L. Heaton, Anna Senina, et al. · Blood · 1
BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia
2013 · Anna M. Eiring, Ira L. Kraft, et al. · Blood · 1
Abstract 3762: Second generation PIM inhibitors exhibit improved activity in solid tumor models
2012 · Jason M. Foulks, Yong Xu, et al. · Cancer Research · 1
Abstract C200: Second-generation PIM inhibitors exhibit improved activity in solid tumor models in vitro.
2011 · Jason M. Foulks, Yong Xu, et al. · Molecular Cancer Therapeutics · 1
Data from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
2023 · Dongqing Yan, Anca Franzini, et al.
Supplementary Table 7 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
2023 · Dongqing Yan, Anca Franzini, et al.
Works count: 73
Citation count: 848
H-index: 11
I10-index: 11
Year
Topic
Type